New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

AI Briefing

• – Annualized height velocity at Week 52 for TransCon hGH-treated children was similar to daily somatropin-treated children.
• – Similar efficacy and safety profile of TransCon hGH compared to daily somatropin.
• – Comparable results in terms of growth hormone efficacy and safety observed at 52 weeks.